Nanus, David M

Publications

Sort by

Co-Author Network

selected publications

NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma. Cancer biology & therapy. 2023 Academic Article GET IT
Novel genetically engineered mouse models for clear cell renal cell carcinoma. Scientific reports. 2023 Academic Article GET IT
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Editorial: Molecular genetics and therapeutic advances in renal carcinoma. Frontiers in oncology. 2023 Editorial Article GET IT
Times cited: 259
Fatalistic cancer beliefs and self-reported cancer screening behaviors among diverse urban residents. Journal of behavioral medicine. 2022 Academic Article GET IT
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. eLife. 2022 Academic Article GET IT
Times cited: 4
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR). Molecular carcinogenesis. 2022 Academic Article GET IT
Times cited: 2
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
Times cited: 4
Cancer and cardiovascular-related perceived risk in a diverse cancer center catchment area. Cancer causes & control : CCC. 2022 Academic Article GET IT
Times cited: 2
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
Times cited: 6
Nearly All Cancer Survivors Return to Primary Care. Journal of the American Board of Family Medicine : JABFM. 2022 Academic Article GET IT
Times cited: 1
Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 242
Highly portable quantitative screening test for prostate-specific antigen at point of care. Current research in biotechnology. 2021 Academic Article GET IT
Times cited: 21
A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. 2021 GET IT
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
Times cited: 6
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications biology. 2021 Academic Article GET IT
Times cited: 3
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 21
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 11
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular cancer research : MCR. 2021 Academic Article GET IT
Times cited: 10
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 198
Eliciting the Social Determinants of Cancer Prevention and Control in the Catchment of an Urban Cancer Center. Ethnicity & disease. 2021 Academic Article GET IT
Times cited: 2
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. The Prostate. 2021 Academic Article GET IT
Times cited: 7
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 13
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 40
Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. Journal of cancer survivorship : research and practice. 2020 Academic Article GET IT
Times cited: 5
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 48
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urologic oncology. 2020 Academic Article GET IT
Times cited: 20
Differences in ambulatory care fragmentation between cancer survivors and noncancer controls. Cancer. 2020 Academic Article GET IT
Times cited: 3
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 88
Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells. Oncogenesis. 2020 Academic Article GET IT
Times cited: 254
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Times cited: 32
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The oncologist. 2020 Academic Article GET IT
Times cited: 24
All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). European journal of haematology. 2020 Academic Article GET IT
Times cited: 20
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational new drugs. 2020 Academic Article GET IT
Times cited: 8
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Translational oncology. 2019 Academic Article GET IT
Times cited: 20
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. PloS one. 2019 Academic Article GET IT
Times cited: 8
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Genes, chromosomes & cancer. 2019 Academic Article GET IT
Times cited: 14
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 138
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 105
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 102
Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Comment GET IT
Times cited: 5
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2019 Academic Article GET IT
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 73
Prostate Cancer National Summit's Call to Action. Clinical genitourinary cancer. 2019 Academic Article GET IT
Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical biology. 2019 Academic Article GET IT
Times cited: 10
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science translational medicine. 2019 Academic Article GET IT
Times cited: 83
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 218
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. 2019 GET IT
Times cited: 4
Expression of AR-V7 and ARv^567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 74
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
Patient derived organoids to model rare prostate cancer phenotypes. Nature communications. 2018 Academic Article GET IT
Times cited: 203
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European urology. 2018 Academic Article GET IT
Times cited: 90
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 6
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2017 Academic Article GET IT
Times cited: 33
Using circulating tumor cells to advance precision medicine in prostate cancer. Journal of cancer metastasis and treatment. 2017 Academic Article GET IT
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 55
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 584
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 201
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic oncology. 2016 Academic Article GET IT
Times cited: 36
Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States. European urology. 2016 Letter GET IT
Times cited: 4
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thrombosis research. 2016 Academic Article GET IT
Recent advances in the management of renal cell carcinoma. F1000Research. 2016 Review GET IT
Times cited: 4274
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 881
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature medicine. 2016 Academic Article GET IT
Times cited: 933
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 17
Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 37
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Current radiopharmaceuticals. 2016 Review GET IT
Times cited: 54
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 101
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 70
The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma. European urology. 2015 Editorial Article GET IT
Times cited: 7
CANCER. Cancer therapies that are gone with the Wnt. Science (New York, N.Y.). 2015 Comment GET IT
Times cited: 4
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical reviews in oncology/hematology. 2015 Review GET IT
Times cited: 37
Kidney cancer: Novel targets in altered tumour metabolism in kidney cancer. Nature reviews. Urology. 2015 Comment GET IT
Times cited: 6
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Article GET IT
Times cited: 340
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 216
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2094
Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma. PloS one. 2015 Academic Article GET IT
Times cited: 25
Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome. Molecular cancer research : MCR. 2015 Academic Article GET IT
Times cited: 19
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 91
Anti-tumor effect of novel cationic biomaterials in prostate cancer. Anticancer research. 2014 Academic Article GET IT
Times cited: 15
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Molecular diagnosis & therapy. 2014 Academic Article GET IT
Times cited: 39
The role of HIF1α in renal cell carcinoma tumorigenesis. Journal of molecular medicine (Berlin, Germany). 2014 Review GET IT
Times cited: 69
In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells. Journal of visualized experiments : JoVE. 2014 Academic Article GET IT
Times cited: 2
Immunologics and chemotherapeutics for renal cell carcinoma. Seminars in interventional radiology. 2014 Review GET IT
Times cited: 9
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer research. 2014 Academic Article GET IT
Times cited: 193
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS one. 2013 Academic Article GET IT
Times cited: 34
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2013 Academic Article GET IT
Times cited: 90
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Frontiers in oncology. 2013 Academic Article GET IT
Times cited: 21
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 321
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer research. 2013 Academic Article GET IT
Times cited: 36
2-weekly versus 3-weekly docetaxel for prostate cancer. The Lancet. Oncology. 2013 Comment GET IT
Times cited: 2
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 190
Challenges in recognizing treatment-related neuroendocrine prostate cancer. 2012 GET IT
Times cited: 163
Negative regulation of NEP expression by hypoxia. The Prostate. 2012 Academic Article GET IT
Times cited: 10
Isolation and characterization of circulating tumor cells in prostate cancer. Frontiers in oncology. 2012 Academic Article GET IT
Times cited: 72
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer research. 2012 Review GET IT
Times cited: 123
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. European urology. 2012 Academic Article GET IT
Times cited: 328
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer. International journal of oncology. 2012 Academic Article GET IT
Times cited: 5
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one. 2012 Academic Article GET IT
Times cited: 181
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European urology. 2011 Review GET IT
Times cited: 147
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011 Academic Article GET IT
Times cited: 633
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 9
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer research. 2011 Academic Article GET IT
Times cited: 77
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 356
Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). The Journal of urology. 2011 Academic Article GET IT
Times cited: 53
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Medical oncology (Northwood, London, England). 2011 Academic Article GET IT
Times cited: 98
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. 2010 GET IT
Times cited: 47
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer biology & therapy. 2010 Academic Article GET IT
Times cited: 18
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urologic oncology. 2010 Academic Article GET IT
Times cited: 13
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 122
Is methylation the key to CD10 loss?. Journal of pediatric hematology/oncology. 2010 Academic Article GET IT
Times cited: 10
Recent advances in management of renal cancer. F1000 medicine reports. 2009 Academic Article GET IT
Times cited: 102
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a chip. 2009 Academic Article GET IT
Times cited: 317
Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. Journal of medical case reports. 2009 Academic Article GET IT
Times cited: 31
Neutral endopeptidase is a myristoylated protein. Molecular and cellular biochemistry. 2009 Academic Article GET IT
Times cited: 6
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2009 Academic Article GET IT
Times cited: 113
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 37
Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochemical pharmacology. 2009 Academic Article GET IT
Times cited: 32
Rational redesign of neutral endopeptidase binding to merlin and moesin proteins. Protein science : a publication of the Protein Society. 2009 Academic Article GET IT
Times cited: 2
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009 Academic Article GET IT
Times cited: 60
Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Molecular carcinogenesis. 2009 Academic Article GET IT
Times cited: 24
Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer biology & therapy. 2008 Academic Article GET IT
Times cited: 34
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clinical genitourinary cancer. 2008 Academic Article GET IT
Times cited: 8
Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2008 Academic Article GET IT
Times cited: 2
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. The Prostate. 2008 Academic Article GET IT
Times cited: 30
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clinical genitourinary cancer. 2007 Academic Article GET IT
Times cited: 34
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. International journal of oncology. 2007 Academic Article GET IT
Times cited: 25
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2007 Academic Article GET IT
Times cited: 40
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis. Prostate cancer and prostatic diseases. 2007 Academic Article GET IT
Times cited: 11
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. The Journal of urology. 2007 Academic Article GET IT
Times cited: 205
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 308
Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochimica et biophysica acta. 2007 Academic Article GET IT
Times cited: 34
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer gene therapy. 2007 Academic Article GET IT
Times cited: 13
Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. The Journal of urology. 2007 Academic Article GET IT
Times cited: 90
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 198
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. Journal of translational medicine. 2007 Academic Article GET IT
Times cited: 28
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer. 2006 Academic Article GET IT
Times cited: 26
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. The Journal of urology. 2006 Academic Article GET IT
Times cited: 64
Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. The Journal of urology. 2006 Academic Article GET IT
Times cited: 39
Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter. Molecular and cellular endocrinology. 2006 Academic Article GET IT
Times cited: 19
Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. The Journal of biological chemistry. 2006 Academic Article GET IT
Times cited: 41
Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene. 2006 Academic Article GET IT
Times cited: 47
Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene. 2006 Academic Article GET IT
Times cited: 64
Chemotherapy for non-clear-cell renal cell carcinoma. Clinical genitourinary cancer. 2006 Review GET IT
Times cited: 12
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clinical genitourinary cancer. 2006 Review GET IT
Times cited: 23
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis. 2005 Academic Article GET IT
Times cited: 26
Antibody-based therapeutics: focus on prostate cancer. Cancer metastasis reviews. 2005 Review GET IT
Times cited: 39
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 112
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 83
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 67
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 428
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 127
Retinoid receptor mRNA expression profiles in human bladder cancer specimens. International journal of oncology. 2005 Academic Article GET IT
Times cited: 11
Involvement of neutral endopeptidase in neoplastic progression. Biochimica et biophysica acta. 2004 Review GET IT
Times cited: 91
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 158
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. British journal of cancer. 2004 Academic Article GET IT
Times cited: 24
Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 47
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 292
Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 28
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer cell. 2004 Academic Article GET IT
Times cited: 131
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. The Journal of biological chemistry. 2004 Academic Article GET IT
Times cited: 37
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 19
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer cell. 2004 Academic Article GET IT
Times cited: 89
Of peptides and peptidases: the role of cell surface peptidases in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Editorial Article GET IT
Times cited: 36
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. The Journal of urology. 2003 Review GET IT
Times cited: 122
Management of bone loss in men with prostate cancer. The Journal of urology. 2003 Review GET IT
Times cited: 37
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. The Journal of urology. 2003 Conference Paper GET IT
Times cited: 4
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. The Journal of urology. 2003 Academic Article GET IT
Times cited: 207
Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 21
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in oncology. 2003 Review GET IT
Times cited: 136
Chemotherapeutic strategies for renal cell carcinoma. The Urologic clinics of North America. 2003 Review GET IT
Times cited: 30
High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002 Academic Article GET IT
Times cited: 165
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 19
The utility of monoclonal antibodies in the imaging of prostate cancer. Seminars in urologic oncology. 2002 Review GET IT
Times cited: 40
Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 39
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer research. 2002 Academic Article GET IT
Times cited: 56
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002 Review GET IT
Times cited: 90
Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase. Anticancer research. 2002 Academic Article GET IT
Times cited: 8
Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?. Cancer investigation. 2002 Editorial Article GET IT
Advanced renal cell carcinoma. Current treatment options in oncology. 2001 Review GET IT
Times cited: 13
Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 55
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer research. 2001 Academic Article GET IT
Times cited: 74
Reduced levels of retinyl esters and vitamin A in human renal cancers. Cancer research. 2001 Academic Article GET IT
Times cited: 44
Orthotopic model of renal cell carcinoma. Methods in molecular medicine. 2001 Academic Article GET IT
Renal cell carcinoma and interferon at the millennium. Cancer investigation. 2001 Review GET IT
Times cited: 6
Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Molecular and cellular endocrinology. 2000 Academic Article GET IT
Times cited: 63
Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. The Journal of clinical investigation. 2000 Academic Article GET IT
Times cited: 124
Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. Cancer research. 2000 Academic Article GET IT
Times cited: 37
Interaction of retinoic acid and interferon in renal cancer cell lines. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2000 Academic Article GET IT
Times cited: 17
New treatment approaches for metastatic renal cell carcinoma. Current oncology reports. 2000 Review GET IT
Times cited: 4
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 249
Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology. 2000 Academic Article GET IT
Times cited: 54
Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 68
Novel investigative approaches for advanced renal cell carcinoma. Seminars in oncology. 2000 Review GET IT
Times cited: 24
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 48
Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. British journal of cancer. 2000 Academic Article GET IT
Times cited: 15
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 53
Decision to operate, radiate, or watch and wait: the prostate cancer dilemma. Cancer investigation. 1999 Editorial Article GET IT
Aminopeptidase A expression and enzymatic activity in primary human renal cancers. International journal of oncology. 1998 Academic Article GET IT
Times cited: 21
Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinomas. Anticancer research. 1998 Academic Article GET IT
Times cited: 4
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature medicine. 1998 Academic Article GET IT
Times cited: 245
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate. Urologic oncology. 1998 Academic Article GET IT
Times cited: 1
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. The Prostate. 1997 Academic Article GET IT
Times cited: 85
Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers. Urology. 1997 Academic Article GET IT
Times cited: 13
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Investigational new drugs. 1997 Academic Article GET IT
Times cited: 28
Renal cell carcinoma. Current problems in cancer. 1997 Review GET IT
Times cited: 105
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. The Journal of clinical endocrinology and metabolism. 1996 Academic Article GET IT
Times cited: 210
Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. The Journal of urology. 1996 Academic Article GET IT
Times cited: 21
Mutation and expression of the low affinity neurotrophin receptor in human malignant melanoma. Melanoma research. 1996 Academic Article GET IT
Times cited: 9
Renal-cell carcinoma. The New England journal of medicine. 1996 Review GET IT
Times cited: 1590
Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. International journal of oncology. 1996 Academic Article GET IT
Times cited: 6
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 66
Expression of the retinoblastoma gene product in renal tumors. Anticancer research. 1996 Academic Article GET IT
Times cited: 14
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology. 1996 Review GET IT
Times cited: 68
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 156
Mutation and expression of the p53 gene in human malignant melanoma. Melanoma research. 1994 Academic Article GET IT
Times cited: 160
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 129
Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene. 1993 Academic Article GET IT
Times cited: 55
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. International journal of cancer. 1993 Academic Article GET IT
Times cited: 234
Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proceedings of the National Academy of Sciences of the United States of America. 1993 Academic Article GET IT
Times cited: 110
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Human gene therapy. 1992 Academic Article GET IT
Times cited: 27
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene. 1992 Academic Article GET IT
Times cited: 54
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. The Journal of thoracic and cardiovascular surgery. 1992 Academic Article GET IT
Times cited: 17
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer research. 1992 Academic Article GET IT
Times cited: 49
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 70
Transformation of human kidney proximal tubule cells by a src-containing retrovirus. Oncogene. 1991 Academic Article GET IT
Times cited: 19
alpha-Interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. Cancer research. 1991 Academic Article GET IT
Times cited: 44
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer research. 1991 Academic Article GET IT
Times cited: 174
Lack of evidence of Ki-ras codon 12 mutations in melanocytic lesions. Journal of cutaneous pathology. 1991 Academic Article GET IT
Times cited: 11
Mutational analysis of the human p53 gene in malignant melanoma. Pigment cell research. 1991 Academic Article GET IT
Times cited: 91
Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer research. 1990 Academic Article GET IT
Times cited: 79
Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology. 1990 Academic Article GET IT
Times cited: 69
Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation. Oncogene. 1990 Academic Article GET IT
Times cited: 37
Infrequent ras oncogene point mutations in renal cell carcinoma. The Journal of urology. 1990 Academic Article GET IT
Times cited: 65
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989 Academic Article GET IT
Times cited: 182
Flow cytometry as a predictive indicator in patients with operable gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Academic Article GET IT
Times cited: 57
Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression. The Journal of experimental medicine. 1989 Academic Article GET IT
Times cited: 12
Systemic chemotherapy in the management of bladder cancer. Cancer treatment and research. 1989 Review GET IT
Times cited: 2
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational new drugs. 1988 Academic Article GET IT
Times cited: 9
Radiation-induced angiosarcoma. Cancer. 1987 Review GET IT
Times cited: 92
B-lymphoproliferative disorders: a proposed unified pathogenetic pathway. 1983 GET IT
Times cited: 3

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Novel Approach to Improving Prostate Cancer Screening Among African American Men awarded by United States Department of Defense Principal Investigator 2022 - 2025
Metabolic and Inflammatory Response to a Whole Food Plant-Based Diet in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Phase II Randomized Study awarded by Prostate Cancer Foundation Principal Investigator 2022 - 2024

Targeting lipid metabolism and diet in patients with locally advanced prostate cancer awarded by Prostate Cancer Foundation Co-Investigator 2023 - 2023
Targeted Therapies awarded by United States Department of Defense Co-Investigator 2022 - 2023
Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity. awarded by United States Department of Defense Co-Investigator 2021 - 2023
Immunogenomic determinants of ethnic disparities in clinical outcomes for urothelial cancer patients awarded by National Human Genome Research Institute Co-Investigator 2020 - 2023
Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYC awarded by National Human Genome Research Institute Co-Investigator 2020 - 2023
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Co-Investigator 2017 - 2023

more ...

less ...

Background

education and training

M.D., Chicago Medical School, Rosalind Franklin University of Medicine and Science 1982
B.S., University of Illinois at Urbana-Champaign 1978

VIVO Weill Cornell Medical College

David M Nanus Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage